Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU) (ELECTRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04207983
Recruitment Status : Active, not recruiting
First Posted : December 23, 2019
Last Update Posted : April 28, 2021
Sponsor:
Information provided by (Responsible Party):
Eyevensys

Brief Summary:
The objective of the study is to evaluate the efficacy and safety of two different treatment regimens of EYS606.

Condition or disease Intervention/treatment Phase
Non-infectious Uveitis Combination Product: EYS606 Phase 2

Detailed Description:

This is a Phase 2, multi-center, randomized open-label interventional study of EYS606 in subjects with active chronic non-infectious uveitis.

The maximum study duration per patient is 51 Weeks (including an up to 3 week screening period + 48 weeks follow-up after treatment).

The study will be conducted in 2 parts. Part I is a safety cohort phase that will enroll up to 6 subjects, Part II is the randomized comparison phase that will enroll up to an additional 50 subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Part I (Safety cohort phase) - no randomization will take place; subjects will be consecutively assigned to one of two sequential safety cohort Regimens and receive two administrations of EYS606

Part II (Randomized comparison phase) - 1:1 randomization to either Treatment Arm A (Regimen 1 or 2 based upon recommendation by the DSMB, n=25) or Treatment Arm B (Regimen 3, n=25)

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 48 Week Phase II, Randomized, Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU)
Actual Study Start Date : February 3, 2020
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : November 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment Arm A (Re-administration)
Two administrations of EYS606 (135μg pEYS606/90 μL). The frequency between the two administrations will be determined by the DSMB upon completion of the Part I safety cohorts.
Combination Product: EYS606
EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle

Experimental: Treatment Arm B (Single administration)
One administration of EYS606 (135μg pEYS606/90 μL) at the baseline visit (V1).
Combination Product: EYS606
EYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle




Primary Outcome Measures :
  1. Time to rescue therapy between the two EYS606 treatment regimens [ Time Frame: Week 24 ]
    Assessment of efficacy measured as time to rescue therapy required after treatment with EYS606


Secondary Outcome Measures :
  1. Proportion (%) of subjects responded to the treatment [ Time Frame: Week 8 and 24 ]
    Measured as an improvement in anterior cell grade and vitreous haze grade according to the SUN scale, retinal vessel leakage using fluorescein angiography, central retinal thickness using ocular coherence tomography, and an increase in visual acuity using EDTRS compared to baseline

  2. Proportion (%) of subjects achieving and maintaining active chronic noninfectious posterior uveitis (CNIU) [ Time Frame: Week 24 ]
    Measured as an improvement in anterior cell grade and vitreous haze grade according to the SUN scale, retinal vessel leakage using fluorescein angiography, central retinal thickness using ocular coherence tomography, and an increase in visual acuity using EDTRS compared to baseline

  3. Median time to control of active CNIU [ Time Frame: Each Visit up to Week 48 ]
    Measured as an improvement in anterior cell grade and vitreous haze grade according to the SUN scale, retinal vessel leakage using fluorescein angiography, and central retinal thickness using ocular coherence tomography

  4. Median time to loss of treatment effect [ Time Frame: Each Visit up to Week 48 ]
    Measured as an worsening in anterior cell grade and vitreous haze grade according to the SUN scale, retinal vessel leakage using fluorescein angiography, central retinal thickness using ocular coherence tomography, decrease in visual acuity using EDTRS, and any increase in the frequency of dose of specified concomitant medications

  5. Median change in visual acuity [ Time Frame: Each Visit up to Week 48 ]
    Measured in change from baseline in best-corrected visual acuity using EDTRS



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Eligibility Criteria:

  1. Subject must be 18 years of age or older.
  2. Subject must have a diagnosis of chronic non-infectious uveitis of any anatomic subtype (anterior, intermediate, posterior or panuveitis).
  3. Subject must have a history of chronic or recurrent non-infectious uveitis requiring or having required treatment with corticosteroids (systemic, periocular or intraocular) and/or systemic immunosuppressive medication(s) in the 12 months prior to the screening visit.
  4. Best corrected visual acuity of

    • Study Part I: ≥ 5 and < 67 ETDRS letters in the study eye (equivalent to less than or equal to 20/50 but better than or equal to 20/800 Snellen).
    • Study Part II: ≥ 5 and < 77 ETDRS letters in the study eye (equivalent to less than or equal to 20/32 but better than or equal to 20/800 Snellen).
  5. At the screening and baseline visits subject must have active chronic non-infectious uveitis as evidenced by at least one or more of the following in the study eye:

    • Active retinal vasculitis (retinal vascular leakage) involving the posterior pole confirmed by the reading center.
    • Vitreous haze grade ≥ 2+ (SUN classification).
    • Anterior chamber cell grade ≥ 2+ (SUN classification); anterior chamber cells must be present for subjects with a diagnosis of chronic anterior non-infectious uveitis.
    • Persistent macular edema (defined as central retinal thickness (CRT) > 300 microns or > 320 microns using Zeiss Cirrus and Topcon or Heidelberg Spectralis spectral domain ocular coherence tomography (SD-OCT) instruments, respectively) despite treatment with corticosteroids and/or immunosuppressive therapy for at least 4 weeks prior to screening.
  6. Subject receiving concomitant topical and/or systemic corticosteroids or allowed systemic immunosuppressive medications must have maintained the same treatment regimen (dosage/frequency) for at least 2 weeks prior to the baseline (V1) visit, (if applicable).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04207983


Locations
Layout table for location information
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 93309
United States, Texas
Texas Retina Associates
Arlington, Texas, United States, 76012
Houston Eye Associates
Houston, Texas, United States, 77025
Sponsors and Collaborators
Eyevensys
Publications:
Layout table for additonal information
Responsible Party: Eyevensys
ClinicalTrials.gov Identifier: NCT04207983    
Other Study ID Numbers: EYS606-CT2
First Posted: December 23, 2019    Key Record Dates
Last Update Posted: April 28, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Uveitis
Uveal Diseases
Eye Diseases